GW Phar­ma’s ral­ly rolls on as cannabi­noid drug scores again in PhI­II Epid­i­olex an­ti-con­vul­sive study

GW Phar­ma­ceu­ti­cals’ late-stage cannabi­noid high is on a roll.

The UK biotech post­ed strong ef­fi­ca­cy da­ta for its ex­per­i­men­tal an­ti-con­vul­sive ther­a­py Epid­i­olex in treat­ing Lennox …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER